TrialThe Lancet. Oncology2022

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

Jonathan D Schoenfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.